A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy‐associated secondary immunodeficiency

Abstract

Objective: To describe the characteristics of patients suffering from secondary immunodeficiencies (SID) associated with hematological malignancies (HM), who started immunoglobulin replacement therapy (IgRT), physicians' expectations regarding IgRT, and IgRT modalities.Methods: Non-interventional, prospective French cross-sectional study. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cost–utility analysis comparing hospital‐based intravenous immunoglobulin with home‐based subcutaneous immunoglobulin in patients with secondary immunodeficiency

“…Secondary immunodeficiency disease patients are heterogeneous because of their different comorbidities, such as diabetes mellitus (12%), thyroid disease (12%) and chronic obstructive pulmonary disease (7%) . In addition, SID patients are often concurrently treated for their underlying condition, relapsing, refractory or have received a haematopoietic stem‐cell transplant . The heterogeneity of this cohort may explain why our infection rate is different to Compagno's study .…”

“…In contrast, one study reported an annual infection rate per patient as 2·29 on IVIg ( n = 33) and 1·76 on SCIg ( n = 61) . A recent study of 231 SID patients reported an annual infection rate of 2·23, but did not distinguish between treatment mode . Reports on IgG deficiency and the risk of developing infection in SID patients are contradictory.…”

“…Studies reported that while IRT resulted in a decrease in number of infections, this did not change overall survival . Death due to cancer has been reported at 64·8% and is estimated to be 2·5 higher compared to general population .…”

The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments

“…This was an observational, multicenter, prospective study conducted in France in real life conditions. Detailed methods have been extensively described elsewhere [14]. Briefly, consecutive adult patients with HM-associated SID who were newly embarked on IgRT, regardless of brand name, route (IVIg or SCIg) or place (hospital or home) of administration were invited to participate in the study.…”

“…Poor response against pneumococcal vaccines increases the susceptibility of respiratory diseases in NHL patients and justifies the use of IgRT [13]. We recently reported indications, modalities and physicians' expectations when starting IgRT in HM-associated SID in real life setting [14]. Beside CLL or MM, patients with NHL represented a large part of HM patients starting IgRT.…”